This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Novartis Pharmaceuticals Corporation.
Reference
Hua LH, et al. The Impact of Price Reductions After Loss of Exclusivity in a Cost-Effectiveness Analysis: Fingolimod Versus Interferon Beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis. Journal of Managed Care and Specialty Pharmacy 25: No. 4, Apr 2019. Available from: URL: https://doi.org/10.18553/jmcp.2019.25.4.490
Rights and permissions
About this article
Cite this article
Impact of price changes after loss of exclusivity for MS treatments. PharmacoEcon Outcomes News 825, 20 (2019). https://doi.org/10.1007/s40274-019-5786-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5786-9